Antipsychotics and Associated Risk of Out-of-Hospital Cardiac Arrest

Bidragets oversatte titel: Antipsychotics and Associated Risk of Out-of-Hospital Cardiac Arrest

P. Weeke, A. Jensen, F. Folke, G. H. Gislason, J. B. Olesen, E. L. Fosbol, M. Wissenberg, F. K. Lippert, E. F. Christensen, S. L. Nielsen, E. Holm, J. K. Kanters, H. E. Poulsen, L. Kober, C. Torp-Pedersen

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


    Antipsychotic drugs have been associated with sudden cardiac death, but differences in the risk of out-of-hospital cardiac arrest (OHCA) associated with different antipsychotic drug classes are not clear. We identified all OHCAs in Denmark (2001-2010). The risk of OHCA associated with antipsychotic drug use was evaluated by conditional logistic regression analysis in case-time-control models. In total, 2,205 (7.6%) of 28,947 OHCA patients received treatment with an antipsychotic drug at the time of the event. Overall, treatment with any antipsychotic drug was associated with OHCA (odds ratio (OR) = 1.53, 95% confidence interval (CI): 1.23-1.89), as was use with typical antipsychotics (OR = 1.66, CI: 1.27-2.17). By contrast, overall, atypical antipsychotic drug use was not (OR = 1.29, CI: 0.90-1.85). Two individual typical antipsychotic drugs, haloperidol (OR = 2.43, CI: 1.20-4.93) and levomepromazine (OR = 2.05, CI: 1.18-3.56), were associated with OHCA, as was one atypical antipsychotic drug, quetiapine (OR = 3.64, CI: 1.59-8.30).
    Bidragets oversatte titelAntipsychotics and Associated Risk of Out-of-Hospital Cardiac Arrest
    TidsskriftClinical Pharmacology and Therapeutics
    Udgave nummer4
    Sider (fra-til)490-497
    StatusUdgivet - 2014

    Bibliografisk note

    ISI Document Delivery No.: AQ3FN Times Cited: 0 Cited Reference Count: 46 Weeke, P. Jensen, A. Folke, F. Gislason, G. H. Olesen, J. B. Fosbol, E. L. Wissenberg, M. Lippert, F. K. Christensen, E. F. Nielsen, S. L. Holm, E. Kanters, J. K. Poulsen, H. E. Kober, L. Torp-Pedersen, C. Tryg Foundation, TrygFonden, Denmark [7343-09]; Novo Nordisk Foundation P.W. was funded by an unrestricted research grant from the Tryg Foundation ( 7343-09, TrygFonden, Denmark). G.H.G. is supported by an independent research scholarship from the Novo Nordisk Foundation. 0 NATURE PUBLISHING GROUP NEW YORK CLIN PHARMACOL THER